RedHill Biopharma annual stock-based compensation
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
RedHill Biopharma Stock-Based Compensation Growth & History (RDHL)
RedHill Biopharma's stock-based compensation was $457,000 for fiscal 2025.
View full RedHill Biopharma company overviewRedHill Biopharma annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $457,000 | −$208,000 | −31.28% |
| 2024 | 2024-12-31 | $665,000 | −$982,000 | −59.62% |
| 2023 | 2023-12-31 | $1.6M | −$4.0M | −70.98% |
| 2022 | 2022-12-31 | $5.7M | −$4.5M | −44.43% |
| 2021 | 2021-12-31 | $10.2M | $6.0M | +143.03% |
| 2020 | 2020-12-31 | $4.2M | $1.2M | +38.82% |
| 2019 | 2019-12-31 | $3.0M | $349,000 | +13.03% |
| 2018 | 2018-12-31 | $2.7M | $443,000 | +19.82% |
| 2017 | 2017-12-31 | $2.2M | $556,000 | +33.11% |
| 2016 | 2016-12-31 | $1.7M | $315,000 | +23.09% |
| 2015 | 2015-12-31 | $1.4M | — | — |
RedHill Biopharma quarterly stock-based compensation
Q2.17
Q2.18
Q2.19
Q2.20
Q2.21
Q2.22
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2022 | 2022-06-30 | $618,000 | −$4.7M | −88.28% |
| Q2 2021 | 2021-06-30 | $5.3M | $4.7M | +746.55% |
| Q2 2020 | 2020-06-30 | $623,000 | −$314,000 | −33.51% |
| Q2 2019 | 2019-06-30 | $937,000 | $204,000 | +27.83% |
| Q2 2018 | 2018-06-30 | $733,000 | $28,000 | +3.97% |
| Q2 2017 | 2017-06-30 | $705,000 | — | — |
RedHill Biopharma stock-based compensation trends
Over the last five fiscal years, RedHill Biopharma's stock-based compensation decreased from $4.2M to $457,000, a change of −$3.7M. The latest reported quarter, Q2 2022, shows $618,000.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review RedHill Biopharma source filings ↗